Pluri Inc.

PLUR · Nasdaq · Israel

Share price · PLUR

$0.92-0.71 (-43.86%) 3M

close as of 2026-11-18 · 24h delayed · vol 35K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PLUR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026+13.1%
  2. 21 Oct 2026+16.7%
  3. 19 Oct 2026-8.6%
  4. 9 Sep 2026+7.9%

    Nothing announced by PLUR that day or the session before.

  5. 26 Aug 2026-10.8%

    Nothing announced by PLUR that day or the session before.

  6. 24 Aug 2026-8.8%

    Nothing announced by PLUR that day or the session before.

  7. 5 Aug 2026+11.5%

    Nothing announced by PLUR that day or the session before.

  8. 26 Jun 2026-6.0%
  9. 18 Jun 2026-10.2%

    Nothing announced by PLUR that day or the session before.

  10. 21 May 2026-11.5%

    Nothing announced by PLUR that day or the session before.

Share of unusual movement by asset

For each asset, the share of PLUR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—87%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
PLX-PADNo recent activity
Preclinical / Unstaged
Mesenchymal stem cells (immunomodulatory, pro-angiogenic)Cell therapy
Osteoarthritis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.8M$14M$4.5M+ $5.3M short-term inv.$10M-$4.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0.2M$4.0M$4.6M+ $7.1M short-term inv.$5.5M-$4.5M operating cash flowreport ↗
2025-Q4$0.2M$3.8M$5.8M+ $9.0M short-term inv.$6.5M-$5.2M operating cash flowreport ↗
2025-Q3$0.3M$3.9M$5.6M+ $12M short-term inv.$5.8M-$5.4M operating cash flowreport ↗
2025-Q1$0.4M$3.0M$9.7M+ $19M short-term inv.$6.2M-$4.3M operating cash flowreport ↗
2024-Q4$0.2M$2.9M$8.3M+ $15M short-term inv.$3.0M-$4.6M operating cash flowreport ↗
2024-Q3$0.3M$2.9M$4.2M+ $23M short-term inv.$5.9M-$4.1M operating cash flowreport ↗
2024-Q1$0.1M$3.1M$8.0M+ $20M short-term inv.$5.3M-$4.2M operating cash flowreport ↗
2023-Q4$0.1M$3.0M$6.5M$4.9M-$3.6M operating cash flowreport ↗
2023-Q3$0.1M$3.4M$6.2M$5.0M-$5.9M operating cash flowreport ↗
2023-Q1$0.1M$4.3M$4.6M$7.6M-$6.1M operating cash flowreport ↗
2022-Q4$0$4.6M$10M$8.1M-$6.3M operating cash flowreport ↗
2022-Q3$0.1M$4.5M$10M$6.1M-$7.6M operating cash flowreport ↗
2022-Q1$0.2M$6.3M$25M$9.9M-$9.4M operating cash flowreport ↗
2021-Q4—$6.5M$19M+ $39M short-term inv.$11M-$9.9M operating cash flowreport ↗
2021-Q3—$6.4M$15M+ $46M short-term inv.$11M-$8.8M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$1.0M$15M$4.6M+ $5.3M short-term inv.$6.0M-$20M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.3M$13M$7.2M+ $16M short-term inv.$5.7M-$18M operating cash flowreport ↗
2024-FY$0.3M$12M$7.7M+ $24M short-term inv.$5.2M-$18M operating cash flowreport ↗
2023-FY$0.3M$17M$6.3M$7.1M-$23M operating cash flowreport ↗
2022-FY$0.2M$25M$11M$10M-$37M operating cash flowreport ↗
2021-FY—$31M$32M+ $34M short-term inv.$12M-$31M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($1.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-23Manieu Alexandre Weinstein · director, 10% ownerOpen-market purchase833,334$1.50$1.3MForm 4
2026-10-23Manieu Alexandre Weinstein · director, 10% ownerOpen-market purchase (derivative)833,334——Form 4
2026-08-25Manieu Alexandre Weinstein · director, 10% ownerOption exercise641——Form 4
2026-08-20Manieu Alexandre Weinstein · director, 10% ownerAward / grant180,000——Form 4
2026-08-20SHORRER DORON · directorAward / grant31,569——Form 4
2026-06-30Manieu Alexandre Weinstein · director, 10% ownerAward / grant641——Form 4
2026-06-30Manieu Alexandre Weinstein · director, 10% ownerCode E (derivative)625,000——Form 4
2026-04-21Manieu Alexandre Weinstein; Chutzpah Holdings Ltd · director, 10% owner; 10% ownerAward / grant312,500$2.00$625KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 0.0M shares ($91K, 0.2% of shares outstanding).

#InstitutionSharesValue
1RENAISSANCE TECHNOLOGIES LLC19,424$66K
2MORGAN STANLEY3,076$10K
3EverSource Wealth Advisors, LLC2,000$7K
4CITIGROUP INC1,360$5K
5SIMA Wealth Partners, LLC350$1K
6WELLS FARGO & COMPANY/MN185$628
7JPMORGAN CHASE & CO125$420
8SBI Securities Co., Ltd.97$329
9UBS Group AG95$322
10TD Waterhouse Canada Inc.93$312
11OSAIC HOLDINGS, INC.50$170
12Winch Advisory Services, LLC26$88
13TFC Financial Management, Inc.19$65
14ROYAL BANK OF CANADA125$0